2. Search Result
Search Result
Results for "

oral administration

" in MedChemExpress (MCE) Product Catalog:

98

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

12

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108288
    Sulbactam pivoxil

    CP 47904

    		 Beta-lactamase Antibiotic Bacterial Infection
    Sulbactam pivoxil is a proagent of sulbactam. Sulbactam is a β-lactamase inhibitor which poorly adsorbed from gastrointestinal tract. Sulbactam pivoxil has a better absorption than the parent agent and provides high serum levels after oral administration .
    Sulbactam pivoxil
  • HY-A0234
    Stepronin

    Prostenoglycine; TTPG; Tiase

    		 Chloride Channel Endocrinology
    Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin
  • HY-B0967
    Phthalylsulfacetamide

    		Bacterial Infection
    Phthalylsulfacetamide is a sulfa drug, after oral administration, slowly decompose in the intestine,and release sulfacetamide ,generating antibacterial effect.
    Phthalylsulfacetamide
  • HY-N0864
    Macranthoidin B

    Macranthoiside I

    		 Others Cancer
    Macranthoidin B is a major bioactive saponin in rat plasma after oral administration of extraction of saponins from Flos Lonicerae.
    Macranthoidin B
  • HY-N10225
    Thielavin A

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
    Thielavin A
  • HY-146012
    HIV-1 protease-IN-4

    		HIV Infection
    HIV-1 protease-IN-4 (Compound II-22) is a potent HIV-1 protease inhibitor. HIV-1 protease-IN-4 is a proagent of atazanavir. HIV-1 protease-IN-4 as a proagent that delivers the parent 1 to rat plasma with a 5-fold higher AUC and 67-fold higher C24 when compared to oral administration of the parent agent .
    HIV-1 protease-IN-4
  • HY-118683
    KR-31378

    		Potassium Channel Others
    KR-31378 is a neuroprotectant with dose-dependent pharmacokinetic properties and relevant activity in rats. After intravenous and oral administration of KR-31378 in rats, its pharmacokinetic parameters showed dose-dependent changes, such as decreased clearance with increasing doses, good oral absorption, and comparable AUCs for intravenous and oral administration at different doses.
    KR-31378
  • HY-126835
    A924

    		Amino Acid Derivatives Cancer
    A 924 is an amino acid derivative-based, orally active antitumor agent. A 924 is effective in inhibiting ascites tumors in rat models by intraperitoneal injection or oral administration. The LD50 of A 924 in mice is >1.5 g/kg and >4.5 g/kg by intraperitoneal injection or oral administration, respectively. A 924 does not cause teratogenicity or adverse reactions in normal or pregnant mice .
    A924
  • HY-A0234R
    Stepronin (Standard)

    		Chloride Channel Endocrinology
    Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin (Standard)
  • HY-W031110
    2-Methyl-tetrahydro-β-carboline

    2-MTHBC

    		 Drug Metabolite Neurological Disease
    2-Methyl-tetrahydro-β-carboline is a cyclization product of N,N-dimethyltryptamine after oral administration of ayahuasca .
    2-Methyl-tetrahydro-β-carboline
  • HY-W740380
    21-Carboxylic acid triamcinolone acetonide

    		Drug Metabolite Others
    21-Carboxylic acid triamcinolone acetonide is a metabolite produced in the body after oral administration of [14C]-triamcinolone acetonide .
    21-Carboxylic acid triamcinolone acetonide
  • HY-U00122
    Antiulcer Agent 1

    		Drug Derivative Inflammation/Immunology
    Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new agent development.
    Antiulcer Agent 1
  • HY-20559
    4-Chloro-3-nitrobenzoic acid

    		Biochemical Assay Reagents Others
    4-Chloro-3-nitrobenzoic acid has oral activity, and oral administration can affect the synthesis activity of liver proteins and the activities of urokinase and histidine kinase .
    4-Chloro-3-nitrobenzoic acid
  • HY-122307
    Sulisatin

    DAN-603

    		 Bacterial Metabolic Disease
    Sulisatin (DAN-603) is an anionic laxative that is hydrolyzed to diphenolic derivatives by bacterial aryl sulfate sulfohydrolases in the colon during oral administration .
    Sulisatin
  • HY-120639
    BMS-663749 lysine

    		HIV Others
    BMS-663749 lysine is a prodrug of an HIV-1 attachment inhibitor with the potential to enhance the delivery of the parent compound following oral administration.
    BMS-663749 lysine
  • HY-N4173
    8-Oxoepiberberine

    		Drug Metabolite Metabolic Disease
    8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease .
    8-Oxoepiberberine
  • HY-N0856
    Alisol C 23-acetate

    23-O-Acetylalisol C; Alisol C monoacetate

    		 Others Cardiovascular Disease
    Alisol C 23-acetate, a natural product extracted from Alisma orinentale, can significantly and strongly inhibit DTH response after oral administration.
    Alisol C 23-acetate
  • HY-118543
    TM6089

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector .
    TM6089
  • HY-135245
    Ezetimibe hydroxy glucuronide

    SCH 488128; Ezetimibe hydroxy β-D-Glucuronide

    		 Drug Metabolite Cardiovascular Disease
    Ezetimibe hydroxy glucuronide (SCH 488128) is a trace metabolite detected in dog and human plasma samples after oral administration of Ezetimibe (HY-17376) .
    Ezetimibe hydroxy glucuronide
  • HY-123367
    Rubraxanthone

    		Platelet-activating Factor Receptor (PAFR) Others
    Rubraxanthone is a compound with multiple biological activities. Its pharmacokinetic parameters were determined in mice and it showed a certain concentration variation pattern in plasma after oral administration.
    Rubraxanthone
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-129579
    Linadryl

    		Histamine Receptor Others
    Linadryl is a compound with antihistamine and other effects. It has a variable effect on gastric acid secretion after oral administration, and its effect is about half that of Diphenhydramine (HY-B0303).
    Linadryl
  • HY-122307A
    Sulisatin disodium

    DAN-603 disodium

    		 Bacterial Metabolic Disease
    Sulisatin (DAN-603) disodium is an anionic diarrhea-promoting compound. During oral administration, Sulisatin disodium is hydrolyzed to diphenolic derivatives by bacterial aryl sulfate sulfohydrolases in the colon .
    Sulisatin disodium
  • HY-169199
    BAY-405

    		MAP4K Cancer
    BAY-405 (compund 38) is a MAP4K1 inhibitor that exhibits nanomolar potency in biochemical and cellular assays and achieves in vivo exposure after oral administration .
    BAY-405
  • HY-135578
    Artelinic acid

    		Parasite Infection
    Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .
    Artelinic acid
  • HY-24238
    DLCI-1

    		Cytochrome P450 Others
    DLCI-1 is a potent and selective oral inhibitor of cytochrome P450 2A6 (CYP2A6) that markedly reduces nicotine self-administration in both male and female mice.
    DLCI-1
  • HY-165529
    Camostat

    		Ser/Thr Protease Inflammation/Immunology
    Camostat is an orally active trypsin inhibitor. Camostat can reduce pancreatic fibrosis induced by repeated administration of superoxide dismutase inhibitors in rats, and decrease the proliferation and activation of pancreatic stellate cells (PSCs) .
    Camostat
  • HY-102061
    Naronapride dihydrochloride

    ATI 7505 dihydrochloride

    		 5-HT Receptor Others
    Naronapride (dihydrochloride) (ATI 7505 (dihydrochloride)) is a compound that regulates gastrointestinal motility. It is a 5-HT? receptor agonist. It is extensively metabolized after oral administration and is mainly excreted through feces. It has certain pharmacokinetic properties.
    Naronapride dihydrochloride
  • HY-N6910
    Pseudolaric Acid C2

    		Others Metabolic Disease
    Pseudolaric Acid C2, a diterpenoid isolated from Pseudolarix kaempferi, is identified as the specific metabolite of Pseudolaric acid B in plasma, urine, bile and feces after both oral and intravenous administration to rats .
    Pseudolaric Acid C2
  • HY-118301
    ADX71441

    		GABA Receptor Neurological Disease
    ADX71441 is a potent and selective positive allosteric modulator of the GABAB receptor. ADX71441 is bioavailable after oral administration and is brain penetrant. ADX71441 has the potential for research of anxiety, pain and spasticity .
    ADX71441
  • HY-145461
    Hydroxy lenalidomide

    5-Hydroxy lenalidomide

    		 Drug Metabolite Others
    Hydroxy lenalidomide (5-Hydroxy lenalidomide) is a metabolite of lenalidomide that is present as a minor component in plasma and excreta, accounting for less than 5% of the total radioactivity, following oral administration of lenalidomide in healthy male subjects.
    Hydroxy lenalidomide
  • HY-W011309
    1-O-Hexadecylglycerol

    1-O-HDG; HXDG

    		 PPAR PGE synthase Inflammation/Immunology
    1-O-Hexadecylglycerol can up-regulate PPAR-γ expression, inhibit pGE2, and exhibit anti-inflammatory properties . 1-O-Hexadecylglycerol is effective in oral administration .
    1-O-Hexadecylglycerol
  • HY-162893
    SX29

    		Glycosidase Metabolic Disease
    SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
    SX29
  • HY-14795
    Mimopezil

    ZT-1

    		 Cholinesterase (ChE) Neurological Disease
    Mimopezil (ZT-1) is an cholinesterase (ChE) inhibitor that rapidly degrades into the active metabolite Huperzine A (HY-17388) in water or aqueous organic solvents. After oral administration, Mimopezil is rapidly absorbed but has low bioavailability (0.37%) in rats. However, after metabolism, it is converted into Huperzine A, which accumulates in the blood and exhibits strong activity. Following intravenous administration, Mimopezil reaches higher blood concentrations and is also rapidly metabolized into Huperzine A .
    Mimopezil
  • HY-19899
    APD-916

    		Histamine Receptor Neurological Disease
    APD-916 is an H3 receptor antagonist. APD-916 shows good pharmacokinetic properties, and oral administration of APD-916 has been shown to enhance wakefulness in various animal models .
    APD-916
  • HY-122309
    A-71497

    		Antibiotic Infection
    A-71497 is the 3-formyl derivative of the antibiotic Tosufloxacin (HY-B1802). A-71497 can produce high plasma levels of tosufloxacin upon both oral and subcutaneous administration to mice .
    A-71497
  • HY-144110
    HCV-IN-37

    		HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    HCV-IN-37
  • HY-144878
    VPC-70619
    2 Publications Verification

    		 c-Myc Cancer
    VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration .
    VPC-70619
  • HY-149900
    Antiviral agent 33

    		Biochemical Assay Reagents Infection
    Antiviral agent 33 (compound 1c) is a double-stranded DNA (dsDNA) virus inhibitor with IC50 values of 0.0790 and 0.1572 µM for VACV and AdV5, respectively. Antiviral agent 33 also has potential for oral administration .
    Antiviral agent 33
  • HY-108288R
    Sulbactam pivoxil (Standard)

    		Beta-lactamase Antibiotic Bacterial Infection
    Sulbactam pivoxil (Standard)
  • HY-170961
    SDUY816

    		Aminopeptidase Neprilysin Neurological Disease
    SDUY816 is an oral active dual APN/NEP inhibitor, with IC50 values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders .
    SDUY816
  • HY-118426
    (Rac)-Tipifarnib

    (Rac)-IND 58359; (Rac)-R115777

    		 Farnesyl Transferase Ras Cancer
    (Rac)-Tipifarnib ((Rac)-IND 58359; (Rac)-R115777) is a potent farnesyl protein transferase inhibitor that specifically targets the pro-tailation process of Ras proteins. (Rac)-Tipifarnib showed significant in vivo antitumor effects after oral administration to mice .
    (Rac)-Tipifarnib
  • HY-118189
    Misoprostol acid

    		Prostaglandin Receptor Inflammation/Immunology
    Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers . Misoprostol is an oral agent used to induce labor .
    Misoprostol acid
  • HY-122968
    Brocresine

    NSD-1065

    		 Endogenous Metabolite Neurological Disease
    Brocresine (NSD-1065) is an orally active histidine decarboxylase inhibitor and inhibits the formation of histamine from histidine. Brocresine is also a L-amino acid decarboxylase inhibitor with both a peripheral and central action. Brocresine inhibits gastric secretory response to administration of exogenous gastrin .
    Brocresine
  • HY-100085
    21-Desacetyldeflazacort

    21-desDFZ

    		 Drug Metabolite Inflammation/Immunology
    21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration .
    21-Desacetyldeflazacort
  • HY-147152
    1-Myristoyl-3-chloropropanediol

    		Biochemical Assay Reagents Others
    1-Myristoyl-3-chloropropanediol is a 3-monochloropropanediol (3-MCPD) fatty acid ester. 3-MPCD causes nephropathy and tubular hyperplasia and adenomas by chronic oral administration; also reduces fertility, or provokes infertility in rats and suppresses the immune function .
    1-Myristoyl-3-chloropropanediol
  • HY-111073
    Bentysrepinine

    Y101

    		 HBV Infection Inflammation/Immunology
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields .
    Bentysrepinine
  • HY-156466
    QL-1200186

    		JAK Inflammation/Immunology
    QL-1200186 is anorally activeand selective inhibitor ofTYK2. Oral administration of QL-1200186, dose-dependently inhibitsinterferon-γ(IFNγ) production afterinterleukin-12(IL-12) challenge and significantly ameliorates skin lesions in psoriatic mice .
    QL-1200186
  • HY-103459
    CI-1020

    PD156707

    		 Endothelin Receptor Cardiovascular Disease
    CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration .
    CI-1020
  • HY-114452
    LY2940094
    1 Publications Verification

    BTRX-246040

    		 Opioid Receptor Neurological Disease
    LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .
    LY2940094

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: